Pfizer’s Allergan Play Could Deliver Tax-Inversion, But No OTCs
This article was originally published in The Tan Sheet
Executive Summary
Pfizer and Allergan are in friendly merger talks, but the US likely will not be amiable about another pharma giant re-incorporating abroad. Should a deal happen, Allergan’s generic OTC business would not be included, says Teva, awaiting antitrust clearance to close its acquisition of the Irish firm’s generic operations.
You may also be interested in...
President Urges End To Corporate Inversions
In his State of the Union speech, President Obama pledges to “close tax loopholes,” including his continuing efforts to ban U.S. firms from moving their tax headquarters overseas in corporate inversion deals. On the same day Democratic legislators introduced a bill to stop corporate inversions.
Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.